Physician profile
Raza Ali
NPI 1619933074
$749.54
in general payments reported to CMS, 2019-2025
17 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.46 · 2021: $46.67 · 2022: $153 · 2023: $154 · 2024: $165 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379 · Education: $96.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $378.71 |
| Education | $96.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $246.07 | 2022-2024 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $82.99 | 2025 | |
| Baxter Healthcare | $71.13 | 2023 | Renal - Pd |
| Opko Pharmaceuticals, LLC | $69.14 | 2021-2024 | Rayaldee |
| Nxstage Medical, INC. | $55.76 | 2019 | |
| Calliditas Therapeutics US INC. | $26.72 | 2022-2023 | Tarpeyo |
| Glaxosmithkline, LLC. | $23.36 | 2024 | Jesduvroq, Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $21.78 | 2021 | |
| Vifor Pharma, INC. | $19.24 | 2023 | Veltassa |
| Daiichi Sankyo INC. | $19.07 | 2025 | Injectafer |
| Amgen INC. | $18.70 | 2019 | |
| Radiometer America, INC | $18.42 | 2025 | |
| Travere Therapeutics, INC. | $18.17 | 2025 | |
| Eisai INC. | $17.88 | 2025 | |
| Novo Nordisk INC | $14.82 | 2023 | Ozempic, Rybelsus |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $14.82 | 2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raza Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.